Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The intra-/perilesional application of interleukin-2 seems to be a safe and effective
treatment of skin and soft tissue metastases in malignant melanoma. Especially in case of
intransit metastases the overall survival rate is still 20-30%.
However, the management of intransit metastases is sometimes difficult because of frequent
recurrences. IL-2 intralesionally seems to be an non-invasive option as pilot studies
indicate. In this study the safety and efficacy of IL-2 are evaluated.